Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (351-360 of 384) with videos related to

Pageof 39
Sort By:
Blood|September 23, 2010
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA GroupMartin S Tallman, Haesook T Kim, Pau Montesinos, et al.
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Blood|January 20, 2019
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403Wendy Stock, Selina M Luger, Anjali S Advani, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Blood|January 19, 2012
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AMLZejuan Li, Hao Huang, Yuanyuan Li, et al.
The New England Journal of Medicine|December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker, François Guilhot, Stephen G O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2013
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative studyZejuan Li, Tobias Herold, Chunjiang He, et al.
Pageof 39

Showing results (351-360 of 384) with videos related to

Sort By:
Pageof 39
Blood|September 23, 2010
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA GroupMartin S Tallman, Haesook T Kim, Pau Montesinos, et al.
Blood|February 18, 2021
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurinLaura K Schmalbrock, Anna Dolnik, Sibylle Cocciardi, et al.
The New England Journal of Medicine|June 24, 2017
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationRichard M Stone, Sumithra J Mandrekar, Ben L Sanford, et al.
Leukemia|November 7, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AMLGuillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus, et al.
Blood|January 20, 2019
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403Wendy Stock, Selina M Luger, Anjali S Advani, et al.
Leukemia|July 28, 2021
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study resultsFrank G Rücker, Ling Du, Tamara J Luck, et al.
The New England Journal of Medicine|October 31, 2019
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AMLAlexander E Perl, Giovanni Martinelli, Jorge E Cortes, et al.
Blood|January 19, 2012
Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AMLZejuan Li, Hao Huang, Yuanyuan Li, et al.
The New England Journal of Medicine|December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker, François Guilhot, Stephen G O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2013
Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative studyZejuan Li, Tobias Herold, Chunjiang He, et al.
Pageof 39